Healthcare / Drug Manufacturers - Specialty & GenericToronto
$0.15
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 21%
FCF escenarios
weak_data · normalized FCF $14.0M · quality 41.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
67/100
B
Piotroski
7/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$215M
P/E
7.5x
↓EV/EBITDA
5.2x
↓ROE
23.6%
↑Gross Margin
57.3%
↑Debt/Equity
0.32
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+17.0%
FCF CAGR
—
FCF margin
15.6%
FCF / Net income
0.57x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $151.5M · net income $41.9M · FCF $23.7M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $151.5M | $151.5M | $122.3M | $101.1M | $94.5M |
| Net Income | $41.9M | $41.9M | $-16.3M | $-44.5M | $-130.3M |
| EBITDA | $50.3M | $50.3M | $24.4M | $-10.9M | $-94.8M |
| EPS | 0.03 | 0.03 | -0.01 | -0.04 | -0.15 |
| Gross Margin | 57.3% | 57.3% | 49.0% | 21.1% | 17.5% |
| Operating Margin | 21.6% | 21.6% | 12.0% | -25.7% | -51.8% |
| Net Margin | 27.6% | 27.6% | -13.4% | -44.0% | -137.9% |
| Balance Sheet | |||||
| Debt/Equity | 0.32 | 0.32 | 0.59 | 2.74 | 2.14 |
| Current Ratio | 2.23 | 2.23 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $23.7M | $23.7M | $14.0M | $6.6M | $-11.7M |
| Returns | |||||
| ROE | 23.6% | 23.6% | -14.1% | -87.2% | -144.1% |
| Valuation | |||||
| P/E | 7.50 | 7.50 | — | — | — |
| EV/EBITDA | 5.24 | 5.24 | 4.28 | — | — |
| P/B | 1.34 | 1.34 | 0.47 | 0.29 | 0.25 |
| Growth & Yield | |||||
| Revenue Growth | 23.8% | 23.8% | 21.0% | 7.0% | — |
| EPS Growth | 400.0% | 400.0% | 75.0% | 73.3% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
-23.7%
EPS terminal req.
$0.01
Spread vs growth
423.7%
5Y implied EPS CAGR
-11.7%
EPS terminal req.
$0.02
Spread vs growth
411.7%
10Y implied EPS CAGR
-1.4%
EPS terminal req.
$0.03
Spread vs growth
401.4%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+76.5%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.01 → 0.03
Residual
+76.5%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.